CDI Laboratories HuProt v4.0 Human Proteome Microarrays (100) with Biospecimen Screening Service and Analysis

(1) This is a combined synopsis/solicitation for commercial products and/or commercial services prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (2) The solicitation number is 75N95025Q00167 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial product and commercial services and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13'Simplified Acquisition Procedures; and FAR Part 12'Acquisition of Commercial Products and Commercial Services, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL AND OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Institute of Mental Health (NIMH), intends to negotiate and award a purchase order without providing for full and open competition (including brand name) to CDI Laboratories Inc., 12 Oeste Calle Mandez Vigo, Mayaguez, PR 00680-4983 for HuProt v4.0 Human Proteome Microarrays with Biospecimen Screening Service and Analysis. This acquisition is conducted as non-competitive for a commercial product or commercial service and is conducted pursuant to FAR 13.106-1(b)(1). (3) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2025-03, with effective date January 17, 2025. (4) The associated NAICS code is 541380 and the small business size standard is $19 million. (5) This requirement is for the following: HuProt v4.0 Human Proteome Microarrays with Biospecimen Screening Service and Analysis. Please see the attached Purchase Description for detailed requirements. (6) The NIMH's Translational Immunopsychiatry Unit (TIU) is engaged in autoantibody discovery and validation. Toward this end, it seeks to purchase human protein arrays that have been synthesized in a eukaryotic expression system (HuProt and VirD). The TIU will use these arrays as an unbiased reagent to screening for autoantibodies that bind to conformational and/or post-translationally modified human proteins. (7) The Government anticipates awarding a firm fixed-price purchase order for this acquisition, and the anticipated period of performance is March 17, 2025 - June 17, 2025. (8) The provision at Federal Acquisition Regulation (FAR) 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html https://www.acquisition.gov/caac-letters (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Nov 2024) FAR 52.204-8, Annual Representations and Certifications (JAN 2025) (DEVIATION FEB 2025) See CAAC_Letter_2025-01_Supplement-1.pdf and CAAC_Letter_2025-02_Supplement-1.pdf FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.212-1, Instructions to Offerors-Commercial Products and Commercial Services (Sep 2023) FAR 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services (May 2024) (DEVIATION Feb 2025) CAAC_Letter_2025-01_Supplement-1.pdf and CAAC_Letter_2025-02_Supplement-1.pdf Health and Human Services Acquisition Regulation (HHSAR) 352-259.73, Electronic and Information Technology Accessibility Notice (December 18, 2015) (9) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. The anticipated contract/order will incorporate one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html https://www.acquisition.gov/caac-letters (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4, Contract Terms and Conditions-Commercial Products and Commercial Services (Nov 2023). Applicable addendum to this clause is included as an attachment. HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.239-74, Electronic and Information Technology Accessibility (December 18, 2015) (10) The following provisions and clauses apply to this acquisition and are attached in full text. Offerors MUST complete attachments FAR 52.2024-24, FAR 52.204-26 and submit completed copies as separate documents with their quotation. FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Products and Commercial Services (Jan 2025) (DEVIATION Feb 2025) Per CAAC Letters 2025-01 and 2025-02, FAR 52.222-21 Prohibition of Segregated Facilities and FAR 52.222-26 Equal Opportunity will not be considered when making award decisions or enforce requirements. HHSAR 352.239-78 Information and Communication Technology Accessibility Notice HHSAR 352.239-79 Information and Communication Technology Accessibility FAR DEVIATION STATEMENT: TCAAC Letter 2025-01-Supplement 1 and CAAC Letter 2025-02-Supplement 1 are applicable to this acquisition. System updates may lag policy updates. The System for Award Management (SAM) may continue to require entities to complete representations based on provisions that are not included in agency solicitations. Examples include 52.222-25, Affirmative Action Compliance, and paragraph (d) of 52.212-3, Offeror Representations and Certifications'Commercial Products and Commercial Services. Contracting officers will not consider these representations when making award decisions or enforce requirements. Entities are not required to, nor are they able to, update their entity registration to remove these representations in SAM. The mentioned CAAC Letters may be accessed electronically at this address: CAAC Letters | Acquisition.GOV. (11) The following invoice instruction is included and will be incorporated in the contract/order: NIH Invoice and Payment Provisions with IPP (Mar 2023) (12) The provision at FAR clause 52.212-2, Evaluation-Commercial Products and Commercial Services (Nov 2021), applies to this acquisition. (a) The Government will award a contract/order resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate quotes: technical capability of the product offered to meet the Government requirement; past performance [see FAR 13.106-2(b)(3)]; and price. Technical capability and past performance, when combined, are significantly more important than price. (b) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the quotation, shall result in a binding contract without further action by either party. Before the quotation's specified expiration time, the Government may accept a quotation (or part of a quotation), regardless of whether there are negotiations after its receipt, unless a written notice of withdrawal is received before a contract/order is awarded. (13) Offerors must include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services (May 2024) (DEVIATION Feb 2025), with the offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. See DEVIATION STATEMENT above regarding applicable CAAC Letters. (15) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (16) This combined synopsis/solicitation includes the following attachments: Purchase Description Attachment FAR 52.212-5 (Jan 2025) - revised per CAAC 2025-01 2025-02 Attachment FAR 52.204-24 Attachment FAR 52.204-26 Attachment FAR 52.212-4 - Addendum Attachment HHSAR 352.232-78 and -79 Invoice Provisions and Instructions with IPP (17) Responses to this solicitation must include clear and convincing evidence of the offeror's capability to fulfill the requirement as stated in the Purchase Description. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), service catalog number(s), product description and any other information or factors that may be considered in the award decision. The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All quotations must be received by Tuesday, March 11, 2025 at 9:00 am Eastern Daylight/Standard Time and reference Solicitation Number 75N95025Q00162. Responses must be submitted electronically to Marlene Milgram, Contracting Officer, at marlene.milgram@nih.gov. Fax responses will not be accepted. A determination by the Government whether to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered to determine whether to proceed on a non-competitive basis as indicated above, or to conduct a competitive procurement.